Actively Recruiting
Evaluation of HIP2602 Safety and Effectiveness in Men With Erectile Dysfunction Using Daily Oral Treatment in a Randomized, Double-Blind Trial
Led by Hanmi Pharmaceutical Company Limited · Updated on 2026-10-27
225
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, randomized, double-blind phase 3 trial to evaluate the efficacy and safety of HIP2602 in men with erectile dysfunction. The study focuses on men aged 19 to 75 years who have experienced erectile dysfunction for at least three months and are in a stable sexual relationship. The goal is to understand how HIP2602 affects erectile function compared to control and active comparator drugs. Participants receive daily oral doses of one of three drug combinations HIP2602 plus HPP2602-2 experimental, HPP2602-1 plus HPP2602-2 placebo comparator, or HGP1201 plus HPP2602-1 active comparator. The treatment lasts 12 weeks, during which participants are monitored for changes in erectile function scores and other sexual function measures. The study uses a parallel design with random assignment to the different study groups. During the trial, participants complete questionnaires assessing erectile function and sexual performance at baseline, 6 weeks, and 12 weeks. Researchers track adherence, sexual activity frequency, and safety through scheduled visits. The primary outcome is the change in the International Index of Erectile Function Erectile Function domain score after 12 weeks. Secondary outcomes include changes in other erectile and sexual function domains and participant responses to sexual encounter and global assessment questions. The study is expected to be completed by September 2027.
CONDITIONS
Brief Title
A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
Research Team
J
Jee Won Shon
H
Hyun Jun Park
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here